kwic
risk
risk
right
off
ON
9
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for risk out of >500 occurrences
421954 occurrences (No.40 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to risk]
421954 occurrences (No.40 in the rank) during 5 years in the PubMed. [cache]
| 9) Here, a prospective metagenomic analysis of the gut microbiota of infants at risk of CD was done to track shifts in the microbiota before CD development. |
| PMID:34253606 DOI:10.1073/pnas.2020322118 |
| 2021 Proceedings of the National Academy of Sciences of the United States of America |
| * Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study. |
| - Other than exposure to gluten and genetic compatibility, the gut microbiome has been suggested to be involved in celiac disease (CD) pathogenesis by mediating interactions between gluten/environmental factors and the host immune system. However, to establish disease progression markers, it is essential to assess alterations in the gut microbiota before disease onset. Here, a prospective metagenomic analysis of the gut microbiota of infants at risk of CD was done to track shifts in the microbiota before CD development. We performed cross-sectional and longitudinal analyses of gut microbiota, functional pathways, and metabolites, starting from 18 mo before CD onset, in 10 infants who developed CD and 10 matched nonaffected infants. Cross-sectional analysis at CD onset identified altered abundance of six microbial strains and several metabolites between cases and controls but no change in microbial species or pathway abundance. Conversely, results of longitudinal analysis revealed several microbial species/strains/pathways/metabolites occurring in increased abundance and detected before CD onset. These had previously been linked to autoimmune and inflammatory conditions (e.g., Dialister invisus, Parabacteroides sp., Lachnospiraceae, tryptophan metabolism, and metabolites serine and threonine). Others occurred in decreased abundance before CD onset and are known to have anti-inflammatory effects (e.g., Streptococcus thermophilus, Faecalibacterium prausnitzii, and Clostridium clostridioforme). Additionally, we uncovered previously unreported microbes/pathways/metabolites (e.g., Porphyromonas sp., high mannose-type N-glycan biosynthesis, and serine) that point to CD-specific biomarkers. Our study establishes a road map for prospective longitudinal study designs to better understand the role of gut microbiota in disease pathogenesis and therapeutic targets to reestablish tolerance and/or prevent autoimmunity. |
[
right
kwic]
(1)139  of |
(11)7 prediction |
(21)3 decision |
(31)2 markers |
| (2)49 factors |
(12)6 stratification |
(22)3 or |
(32)2 mitigation |
| (3)46 for |
(13)5 individuals |
(23)3 patients |
(33)2 population |
| (4)21 *null* | (14)4 genes |
(24)2 (OR |
(34)2 ratio |
| (5)19 factor |
(15)4 populations |
(25)2 among |
(35)2 reduction |
| (6)16 and |
(16)4 score |
(26)2 communication |
(36)2 screening |
| (7)13 assessment |
(17)4 to |
(27)2 communication, |
(37)2 strategies |
| (8)12 in |
(18)4 variants |
(28)2 designations |
|
| (9)8 perception |
(19)3 alleles |
(29)2 group |
|
| (10)7 factors, |
(20)3 assessment, |
(30)2 is |
add keyword
--- WordNet output for risk ---